13.80
-1.50%
Close of 6 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eckert & Ziegler
Its shares trade on XETRA under the ticker EUZ.DE. It has been listed since 25 February 2008. In the fiscal year to 31 December 2025, it reported revenue of €312.0m and net income of €48.8m. At that date it held total assets of €485.7m and shareholders' equity of €251.8m.
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 25 Feb 2008
- Employees
- 825
- Website
- ezag.com ↗
Leadership
Pay as last reported
- Dr. Andreas EckertChairman of the Supervisory Board, since 2023€587,092
- Dr. Harald HasselmannChairman of the Executive Board€636,811
- Prof. Dr. Helmut GrotheDeputy Chairman of the Supervisory Board, since 2014€46,000
- Mr. Joseph HathcockMember of the Group Executive Committee, Isotope Products Segment
- Dr. Gunnar MannMember of the Group Executive Committee, Medical Segment (Operations), since 2025
- Ms. Ana RamirezMember of the Group Executive Committee, Isotope Products Segment
- Mr. Franklin YeagerMember of the Executive Board, Isotope Products Segment, since 2023€1.2m
- Dr. Edgar LoefflerIndependent Member of the Supervisory Board€42,338
- Mr. Albert RupprechtIndependent Member of the Supervisory Board€47,000
- Ms. Paola Eckert-palvariniMember of the Supervisory Board€29,333
- Ms. Jutta LudwigMember of the Supervisory Board, since 2019€460,569
- Ms. Karolin RiehleInvestor Relations, since 2014
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 12
- Social
- 56
- Governance
- 27
- Women in the workforce
- 39%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eckert & Ziegler Strahlen und Medizintechnik AG possesses several strengths that contribute to its success. Firstly, the company has a strong reputation and brand recognition in the field of medical technology. This allows them to attract and retain a talented workforce, ensuring high-quality products and services. Additionally, their extensive experience in the industry has enabled them to develop a wide range of innovative and reliable products.
Weaknesses
- Despite its strengths, Eckert & Ziegler Strahlen und Medizintechnik AG also faces certain weaknesses. One such weakness is its limited global presence compared to some of its competitors. This restricts their market reach and potential for growth in certain regions. Furthermore, the company heavily relies on a few key customers, which poses a risk in case of any disruptions in these relationships.
Opportunities
- There are several opportunities available for Eckert & Ziegler Strahlen und Medizintechnik AG to explore. Expansion into emerging markets presents a promising avenue for growth, as these markets tend to have increasing demand for medical technologies. Moreover, the rise in healthcare expenditure and advancements in technology provide opportunities for the company to develop new and improved products.
Threats
- Alongside opportunities, Eckert & Ziegler Strahlen und Medizintechnik AG also faces certain threats. Intense competition in the medical technology industry poses a challenge to the company's market share and profitability. Additionally, ever-changing regulations and compliance requirements can create hurdles for the company's operations. Economic uncertainties and geopolitical factors also pose potential risks that could impact the company's performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.